Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer

CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605

Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research